Device Trial Radar · NCT07805512
A Study to Evaluate the Effectiveness and Safety of Restylane Shaype in the Improvement of Jawline Definition
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
162
Planned (sponsor's estimate)
Start
Sep 28, 2026
Primary completion
Sep 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- Galderma R&DNot on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, evaluator-blinded, parallel group, no-treatment controlled, multicenter study to evaluate effectiveness and the safety of Restylane Shaype for improvement of jawline definition in China. Subjects of Chinese origin, age 18 years, who are eligible for treatment to improve jawline definition. Study sites is approximately 6. A total of approximately 162 subjects will be randomized (2:1) to either treatment with Restylane Shaype Treatment Group (approximately 108subjects) or no-treatment Control Group (approximately 54 subjects).
Conditions
- Jawline Definition
Interventions
Restylane ShaypeDevice
Restylane Shaype is an injectable, sterile, transparent, biodegradable gel of non-animal crosslinked sodium hyaluronate. Restylane Shaype has the addition of lidocaine hydrochloride. They are supplied in a glass syringe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder rate based on the Blind Evaluators' live assessment using the Galderma Jawline Scale(GJS) .Time frame: At 6 months after the last treatment for the Treatment group and at 6 months after baseline for the Control group.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Galderma Investigational Site #6340
Beijing, Beijing Municipality, China · Not yet recruiting
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.